Journal of Cancer Survivorship

, Volume 12, Issue 6, pp 723–732 | Cite as

Initial validation of the Danish version of the Fear of Cancer Recurrence Inventory (FCRI) in colorectal cancer patients

  • Ida Hovdenak JakobsenEmail author
  • Mette Moustgaard Jeppesen
  • Sébastien Simard
  • Henriette Vind Thaysen
  • Søren Laurberg
  • Therese Juul



The Fear of Cancer Recurrence Inventory (FCRI) is a multidimensional measure for fear of cancer recurrence (FCR). The aim of this study was to assess the psychometric properties of the translated Danish version of the FCRI in a population of colorectal cancer patients.


The English version of the FCRI was forward–backward translated into Danish and pilot tested in a gynaecological cancer population. The psychometric properties of the FCRI were assessed in terms of responsiveness, test–retest reliability and discriminative and convergent validity in a population of colorectal cancer patients by asking them to complete questionnaires at three time points during follow-up. Clinical FCR was defined as ≥ 16 at the FCRI short form.


The participation rate was 57%. A low association was found between higher scores on the FCRI and younger age (r = − 0.29, p = 0.02). A moderate correlation was found between the FCRI score and a measure for worry traits (r = 0.49, p < 0.001). Mean difference in total FCRI score was statistically significant between ‘pre-scan’ and ‘postscan’ (p < 0.001), thus indicating that the FCRI was responsive to change. The FCRI score showed good test–retest reliability (intraclass correlation = 0.84).


The Danish version of the FCRI is a reliable and responsive measure for FCR in colorectal cancer patients and shows acceptable discriminative and convergent validity.

Implications for Cancer Survivors

A valid measure for FCR is crucial in order to identify patients with a need for special attention or interventions for high levels of FCR and to improve future research into FCR among cancer survivors.


Cancer survivorship Fear of recurrence Translation, validity and responsiveness Inventory Colorectal cancer 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Armes J, Crowe M, Colbourne L, Morgan H, Murrells T, Oakley C, et al. Patients’ supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. J Clin Oncol. 2009;27(36):6172–9.CrossRefGoogle Scholar
  2. 2.
    Mikkelsen T, Sondergaard J, Sokolowski I, Jensen A, Olesen F. Cancer survivors’ rehabilitation needs in a primary health care context. Fam Pract. 2009;26(3):221–30.CrossRefGoogle Scholar
  3. 3.
    Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, et al. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013 Sep;7(3):300–22.CrossRefGoogle Scholar
  4. 4.
    Lebel S, Ozakinci G, Humphris G, Mutsaers B, Thewes B, Prins J, et al. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer. 2016;24:3265–8.CrossRefGoogle Scholar
  5. 5.
    Simard S, Savard J, Ivers H. Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. J Cancer Surviv. 2010;4(4):361–71.CrossRefGoogle Scholar
  6. 6.
    Butow PN, Fardell JE, Smith AB. Fear of cancer recurrence: an overview and Australian perspective. Cancer Forum. 2015;39(2):95–100.Google Scholar
  7. 7.
    Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology. 2006;15(4):306–20.CrossRefGoogle Scholar
  8. 8.
    Crist JV, Grunfeld EA. Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psychooncology. 2013;22(5):978–86.CrossRefGoogle Scholar
  9. 9.
    Diefenbach M, Mohamed NE, Horwitz E, Pollack A. Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: the moderating role of age. Psychol Health Med. 2008;13(2):146–61.CrossRefGoogle Scholar
  10. 10.
    Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, et al. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007;16(10):895–903.CrossRefGoogle Scholar
  11. 11.
    Yang Y, Cameron J, Humphris G. The relationship between cancer patient’s fear of recurrence and radiotherapy: a systematic review and meta-analysis. Psychooncology. 2017;26(6):738–46.CrossRefGoogle Scholar
  12. 12.
    Llewellyn CD, Weinman J, McGurk M, Humphris G. Can we predict which head and neck cancer survivors develop fears of recurrence? J Psychosom Res. 2008;65(6):525–32.CrossRefGoogle Scholar
  13. 13.
    Freeman-Gibb LA, Janz NK, Katapodi MC, Zikmund-Fisher BJ, Northouse L. The relationship between illness representations, risk perception and fear of cancer recurrence in breast cancer survivors. Psychooncology. 2017;26(9):1270–7.CrossRefGoogle Scholar
  14. 14.
    Gill KM, Mishel M, Belyea M, Germino B, Germino LS, Porter L, et al. Triggers of uncertainty about recurrence and long-term treatment side effects in older African American and Caucasian breast cancer survivors. Oncol Nurs Forum. 2004;31(3):633–9.CrossRefGoogle Scholar
  15. 15.
    Janz NK, Hawley ST, Mujahid MS, Griggs JJ, Alderman A, Hamilton AS, et al. Correlates of worry about recurrence in a multiethnic population-based sample of women with breast cancer. Cancer. 2011;117(9):1827–36.CrossRefGoogle Scholar
  16. 16.
    Mehnert A, Berg P, Henrich G, Herschbach P. Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors. Psychooncology. 2009;18(12):1273–80.CrossRefGoogle Scholar
  17. 17.
    Thewes B, Butow P, Zachariae R, Christensen S, Simard S, Gotay C. Fear of cancer recurrence: a systematic literature review of self-report measures. Psychooncology. 2012;21(6):571–87.CrossRefGoogle Scholar
  18. 18.
    Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009;17(3):241–51.CrossRefGoogle Scholar
  19. 19.
    Lebel S, Simard S, Harris C, Feldstain A, Beattie S, McCallum M, et al. Empirical validation of the English version of the Fear of Cancer Recurrence Inventory. Qual Life Res. 2016;25(2):311–21.CrossRefGoogle Scholar
  20. 20.
    Shin J, Goo A, Ko H, Kim JH, Lim SU, Lee HK, et al. Validation study for the Korean version of Fear of Cancer Recurrence Inventory. J Korean Med Sci. 2017;32(11):1792–9.CrossRefGoogle Scholar
  21. 21.
    van Helmondt SJ, van der Lee ML, de Vries J. Translation and validation of the Dutch version of the Fear of Cancer Recurrence Inventory (FCRI-NL). J Psychosom Res. 2017;102:21–8.CrossRefGoogle Scholar
  22. 22.
    Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv. 2015;9(3):481–91.CrossRefGoogle Scholar
  23. 23.
    Leeson SC, Beaver K, Ezendam NPM, Mačuks R, Martin-Hirsch PL, Miles T, et al. The future for follow-up of gynaecological cancer in Europe. Summary of available data and overview of ongoing trials. Eur J Obstet Gynecol Reprod Biol. 2017;210(Supplement C):376–80.CrossRefGoogle Scholar
  24. 24.
    Hovdenak Jakobsen I, Juul T, Bernstein I, Christensen P, Jensen FS, Johansen C, et al. Follow-up after rectal cancer: developing and testing a novel patient-led follow-up program. Study Protocol Acta Oncol. 2017;56(2):307–13.CrossRefGoogle Scholar
  25. 25.
    Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2000;25(24):3186–91.CrossRefGoogle Scholar
  26. 26.
    Cull A, Sprangers MA, Bjordal K, Aaronson N. On behalf of the European Organisation for Research and Treatment of Cancer quality of life study group. EORTC quality of life study group translation procedure. Brussels: EORTC; 1998. p. 26.Google Scholar
  27. 27.
    Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539–49.CrossRefGoogle Scholar
  28. 28.
    Postoperativ kontrol. In: DCCG’s nationale retningslinjer for diagnostik og behandling af kolorektal cancer. Danish Colorectal Cancer Group. 2012. Accessed 10 Dec 2016.
  29. 29.
    Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487–95.CrossRefGoogle Scholar
  30. 30.
    Anthoine E, Moret L, Regnault A, Sebille V, Hardouin JB. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes. 2014;12
  31. 31.
    Dinkel A, Kremsreiter K, Marten-Mittag B, Lahmann C. Comorbidity of fear of progression and anxiety disorders in cancer patients. Gen Hosp Psychiatry. 2014;36(6):613–9.CrossRefGoogle Scholar
  32. 32.
    Hvenegaard M, Watkins ER, Poulsen S, Rosenberg NK, Gondan M, Grafton B, et al. Rumination-focused cognitive behaviour therapy vs. cognitive behaviour therapy for depression: study protocol for a randomised controlled superiority trial. Trials. 2015;16
  33. 33.
    Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess. 1994;6(4):284–90.CrossRefGoogle Scholar
  34. 34.
    de Vet HC, Terwee CB, Mokkink LB, Knol DL. Validity. In: de Vet HC, Terwee CB, Mokkink LB, Knol DL, editors. Measurement in medicine. First ed. Cambridge: Cambridge University Press; 2011. p. 150–201.CrossRefGoogle Scholar
  35. 35.
    Korte KJ, Allan NP, Schmidt NB. Factor mixture modeling of the Penn State Worry Questionnaire: evidence for distinct classes of worry. J Anxiety Disord. 2016;37:40–7.CrossRefGoogle Scholar
  36. 36.
    Lampic C, Wennberg A, Schill JE, Brodin O, Glimelius B, Sjoden PO. Anxiety and cancer-related worry of cancer patients at routine follow-up visits. Acta Oncol. 1994;33(2):119–25.CrossRefGoogle Scholar
  37. 37.
    Papagrigoriadis S, Heyman B. Patients’ views on follow up of colorectal cancer: implications for risk communication and decision making. Postgrad Med J. 2003;79(933):403–7.CrossRefGoogle Scholar
  38. 38.
    Stiggelbout AM, de Haes JC, Vree R, van de Velde CJ, Bruijninckx CM, van Groningen K, et al. Follow-up of colorectal cancer patients: quality of life and attitudes towards follow-up. Br J Cancer. 1997;75(6):914–20.CrossRefGoogle Scholar
  39. 39.
    Custers JA, Gielissen MF, Janssen SH, de Wilt JH, Prins JB. Fear of cancer recurrence in colorectal cancer survivors. Support Care Cancer. 2016;24(2):555–62.CrossRefGoogle Scholar
  40. 40.
    Custers JA, van den Berg SW, van Laarhoven HW, Bleiker EM, Gielissen MF, Prins JB. The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors. Cancer Nurs. 2014;37(1):44–50.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of SurgeryAarhus University HospitalAarhus CDenmark
  2. 2.Department of Gynaecology and ObstetricsOdense University HospitalOdense CDenmark
  3. 3.Department of Health SciencesUniversity of Quebec in Chicoutimi (UQAC)ChicoutimiCanada

Personalised recommendations